Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

BACKGROUND: This multicenter, open‐label, phase Ib study investigated the safety and efficacy of binimetinib (MEK inhibitor) in combination with buparlisib (phosphatidylinositol 3‐kinase [PI3K] inhibitor) in patients with advanced solid tumors with RAS/RAF alterations. MATERIALS AND METHODS: Eighty‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardia, Aditya, Gounder, Mrinal, Rodon, Jordi, Janku, Filip, Lolkema, Martijn P., Stephenson, Joe J., Bedard, Philippe L., Schuler, Martin, Sessa, Cristiana, LoRusso, Patricia, Thomas, Michael, Maacke, Heiko, Evans, Helen, Sun, Yongjian, Tan, Daniel S.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
New Drug Development and Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964137/
https://www.ncbi.nlm.nih.gov/pubmed/31395751
http://dx.doi.org/10.1634/theoncologist.2019-0297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964137/
https://www.ncbi.nlm.nih.gov/pubmed/31395751
http://dx.doi.org/10.1634/theoncologist.2019-0297

Ejemplares similares